NZ705575A - Recombinant clostridium botulinum neurotoxins - Google Patents

Recombinant clostridium botulinum neurotoxins

Info

Publication number
NZ705575A
NZ705575A NZ705575A NZ70557513A NZ705575A NZ 705575 A NZ705575 A NZ 705575A NZ 705575 A NZ705575 A NZ 705575A NZ 70557513 A NZ70557513 A NZ 70557513A NZ 705575 A NZ705575 A NZ 705575A
Authority
NZ
New Zealand
Prior art keywords
protein
bont
sequence
soluble
trypsin
Prior art date
Application number
NZ705575A
Other languages
English (en)
Inventor
Aimee Cossins
Matthew Beard
Marks Philip
Original Assignee
Ipsen Bioinnovation Ltd
Ipsen Biopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Bioinnovation Ltd, Ipsen Biopharm Ltd filed Critical Ipsen Bioinnovation Ltd
Publication of NZ705575A publication Critical patent/NZ705575A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893Botulinum neurotoxin (3.4.24.69)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24Metalloendopeptidases (3.4.24)
    • C12Y304/24069Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ705575A 2012-10-31 2013-10-31 Recombinant clostridium botulinum neurotoxins NZ705575A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201219602A GB201219602D0 (en) 2012-10-31 2012-10-31 Recombinant clostridium botulinum neurotoxins
PCT/GB2013/052845 WO2014068317A1 (en) 2012-10-31 2013-10-31 Recombinant clostridium botulinum neurotoxins

Publications (1)

Publication Number Publication Date
NZ705575A true NZ705575A (en) 2019-08-30

Family

ID=47358958

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ705575A NZ705575A (en) 2012-10-31 2013-10-31 Recombinant clostridium botulinum neurotoxins

Country Status (26)

Country Link
US (1) US10030238B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (3) EP3673914B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JP2019068823A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (2) KR102188539B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (2) CN104755098A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (2) AR093309A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (3) AU2013340610B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112015005384A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2885519A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (2) DK3326644T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA201590794A8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (2) ES2788199T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB201219602D0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (2) HUE048802T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL237623B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2015MN00436A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (2) MX367080B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO2914282T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ705575A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (2) PL2914282T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (2) PT3326644T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (2) SG11201502372SA (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (3) TWI673361B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA118837C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2014068317A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA201501449B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201219602D0 (en) * 2012-10-31 2012-12-12 Syntaxin Ltd Recombinant clostridium botulinum neurotoxins
PL3274364T3 (pl) * 2015-03-26 2022-01-10 President And Fellows Of Harvard College Neurotoksyna botulinowa uzyskana technikami inżynierii
WO2017063743A1 (en) 2015-10-14 2017-04-20 Merz Pharma Gmbh & Co. Kgaa Improvements to ultrasound-based therapy of photoaged tissue
ES2893838T3 (es) 2016-03-02 2022-02-10 Merz Pharma Gmbh & Co Kgaa Composición que comprende toxina botulínica
EP3263710A1 (en) * 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
JP7100020B2 (ja) 2016-08-24 2022-07-12 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 操作されたボツリヌス神経毒素
CN117959415A (zh) 2016-09-13 2024-05-03 阿勒根公司 非蛋白质梭菌毒素组合物
WO2018233813A1 (en) 2017-06-20 2018-12-27 Merz Pharma Gmbh & Co. Kgaa NOVEL RECOMBINANT BOTULINUM TOXINS WITH INCREASED DURATION
ES2930237T3 (es) 2017-07-06 2022-12-09 Merz Pharma Gmbh & Co Kgaa Neurotoxinas botulínicas recombinantes nuevas con mayor duración de efectos
AU2018347514C1 (en) 2017-10-11 2025-01-02 Illustris Pharmaceuticals, Inc. Methods and compositions for topical delivery
EP3746463A1 (en) * 2018-01-29 2020-12-09 Ipsen Biopharm Limited Non-neuronal snare-cleaving botulinum neurotoxins
US11707510B2 (en) * 2018-02-16 2023-07-25 Preclinics Discovery Gmbh Nucleic acid-based botulinum neurotoxin for therapeutic use
GB201815844D0 (en) 2018-09-28 2018-11-14 Ipsen Biopharm Ltd Therapeutic & comestic uses of botulinum neurotoxin serotype e
GB202011055D0 (en) 2020-07-17 2020-09-02 Ipsen Bioinnovation Ltd Treatment of post-operative pain
GB202015618D0 (en) * 2020-10-01 2020-11-18 Ipsen Biopharm Ltd Method for producing beta-trypsin
CN115819526A (zh) * 2022-12-02 2023-03-21 海雅美生物技术(珠海)有限公司 一种重组肉毒杆菌神经毒素及其制备方法和应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6967088B1 (en) 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
NZ308772A (en) * 1995-05-17 1999-04-29 Du Pont Recombinant baculovirus insecticides
WO2000002524A2 (en) 1998-07-10 2000-01-20 U.S. Army Medical Research Institute Of Infectious Diseases Botulinum neurotoxin vaccine
EP2267009B1 (en) 1999-08-25 2014-10-29 Allergan, Inc. Activatable recombinant neurotoxins
US7374896B2 (en) 2001-08-28 2008-05-20 Allergan, Inc. GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity
US20110111483A1 (en) 2004-06-30 2011-05-12 Allergan, Inc. Optimizing Expression of Active Botulinum Toxin Type E
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US7825233B2 (en) * 2004-06-30 2010-11-02 Allergan, Inc. Optimizing expression of active Botulinum Toxin type E
GB2416122A (en) * 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
DE102004043009A1 (de) * 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
DE102005002978B4 (de) * 2005-01-21 2013-04-25 Merz Pharma Gmbh & Co. Kgaa Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form
EP1853623B1 (en) * 2005-03-03 2013-05-08 Allergan, Inc. Animal product free system and process for purifying a botulinum toxin
DK1926744T4 (en) * 2005-09-19 2019-01-28 Allergan Inc CLOSTRIDIUM TOXIN-ACTIVABLE CLOSTRIDIAL TOXINES
US20070218084A1 (en) * 2005-12-30 2007-09-20 Fondazione Pierfranco E Luisa Mariani- Onlus Method for the Mapping of the Epileptogenic Focus in the Pre-Surgical Evaluation of Patients with Intractable Epilepsy
AU2007272517B2 (en) * 2006-07-11 2013-09-26 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
US8486422B2 (en) 2007-07-26 2013-07-16 Allergan, Inc. Methods of activating clostridial toxins
KR20110106346A (ko) 2008-12-10 2011-09-28 알러간, 인코포레이티드 클로스트리디움 독소 약제학적 조성물
GB0903006D0 (en) * 2009-02-23 2009-04-08 Syntaxin Ltd Modified non-cytotoxic proteases
US10011823B2 (en) * 2009-04-14 2018-07-03 Medical College Of Wisconsin, Inc. Engineered botulinum neurotoxin
CN102753681A (zh) * 2009-12-16 2012-10-24 阿勒根公司 包含整合型蛋白酶裂解位点-结合结构域的经过修饰的梭菌毒素
US20120207743A1 (en) 2011-02-14 2012-08-16 Allergan, Inc. Inhibiting Aberrant Blood Vessel Formation Using Retargeted Endopeptidases
GB201219602D0 (en) * 2012-10-31 2012-12-12 Syntaxin Ltd Recombinant clostridium botulinum neurotoxins
GB201407525D0 (en) * 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
JP7100020B2 (ja) * 2016-08-24 2022-07-12 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 操作されたボツリヌス神経毒素

Also Published As

Publication number Publication date
KR102264478B1 (ko) 2021-06-15
TW201825680A (zh) 2018-07-16
PL2914282T3 (pl) 2018-07-31
AU2020244481A1 (en) 2020-10-29
EA201590794A8 (ru) 2016-01-29
PT2914282T (pt) 2018-03-13
UA118837C2 (uk) 2019-03-25
TWI626307B (zh) 2018-06-11
ES2788199T3 (es) 2020-10-20
PL3326644T3 (pl) 2020-08-24
HK1208359A1 (en) 2016-03-04
TW202012622A (zh) 2020-04-01
IL237623A0 (en) 2015-04-30
EP3673914B1 (en) 2021-10-27
EA201590794A1 (ru) 2015-08-31
EP2914282B1 (en) 2017-12-20
MX2015005156A (es) 2015-09-23
CN110499321A (zh) 2019-11-26
HUE036764T2 (hu) 2018-07-30
ZA201501449B (en) 2016-08-31
NO2914282T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2018-05-19
US20150247139A1 (en) 2015-09-03
JP2019068823A (ja) 2019-05-09
BR112015005384A2 (pt) 2017-08-08
PT3326644T (pt) 2020-05-29
EP3326644B1 (en) 2020-03-04
WO2014068317A1 (en) 2014-05-08
HUE048802T2 (hu) 2020-08-28
GB201219602D0 (en) 2012-12-12
SG11201502372SA (en) 2015-05-28
SG10201701140WA (en) 2017-04-27
AU2013340610B2 (en) 2018-02-22
MX2019009222A (es) 2019-11-21
IL237623B (en) 2019-05-30
JP2020078321A (ja) 2020-05-28
IN2015MN00436A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-09-04
AU2018203556B2 (en) 2020-08-20
EP3326644A1 (en) 2018-05-30
CN104755098A (zh) 2015-07-01
TW201435084A (zh) 2014-09-16
AU2013340610A1 (en) 2015-03-19
US10030238B2 (en) 2018-07-24
AU2018203556A1 (en) 2018-06-07
DK2914282T3 (en) 2018-02-26
KR20200110470A (ko) 2020-09-23
AR093309A1 (es) 2015-05-27
KR20150094590A (ko) 2015-08-19
CA2885519A1 (en) 2014-05-08
MX367080B (es) 2019-08-05
EP2914282A1 (en) 2015-09-09
DK3326644T3 (da) 2020-05-11
ES2662402T3 (es) 2018-04-06
KR102188539B1 (ko) 2020-12-09
EP3673914A1 (en) 2020-07-01
AR117738A2 (es) 2021-08-25
TWI673361B (zh) 2019-10-01

Similar Documents

Publication Publication Date Title
NZ705575A (en) Recombinant clostridium botulinum neurotoxins
WO2014202616A3 (en) Rasamsonia gene and use thereof
MY187542A (en) Carbohydrate degrading polypeptide and uses thereof
MY160897A (en) Polypeptide having or assisting in carbohydrate material degrading activity and uses thereof
EA201101553A1 (ru) Полипептид, деградирующий углеводы, и его применения
MX2012015142A (es) Polipeptidos que tiene actividad beta-glucosidasa y usos del mismo.
MX2015017110A (es) Integracion dirigida.
WO2014202622A3 (en) Rasamsonia gene and use thereof
PH12017501520A1 (en) Fusarium toxin-cleaving polypeptide variants, additives containing same, use of same, and method for splitting fusarium toxins
NZ742660A (en) Variants of chymosin with improved milk-clotting properties
MX2019003360A (es) Vectores de expresion para una secrecion de proteina mejorada.
EA201300056A1 (ru) Полипептид с активностью ацетилксиланэстеразы и его применения
WO2014122161A3 (en) Use of polypeptides having protease activity in animal feed
MX364390B (es) Uso de polipeptidos que tienen actividad proteasa en alimentos para animales y detergentes.
MX2016012840A (es) Moléculas para transporte de antígeno modular mejoradas y sus usos.
EP4353256A3 (en) Induction of cross-reactive cellular response against rhinovirus antigens
EA201300059A1 (ru) Полипептид, обладающий активностью сволленина, и его применение
NZ709120A (en) Beta-hexosyl-transferases and uses thereof
WO2015108856A3 (en) Methods for enhancing the delivery of active agents
WO2014018689A3 (en) Novel monomeric yellow-green fluorescent protein from cephalochordate
EA201690634A1 (ru) Новая гетеро-трансгликозилаза и ее применение
NZ756533A (en) Recombinant vaccine against helminths in pichia pastoris and methods for producing and purifying proteins for use as vaccines against helminths
IN2014MN00935A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO2014202620A3 (en) Rasamsonia gene and use thereof
MX2015004373A (es) Moleculas de acidos nucleicos para una mayor produccion de proteinas.

Legal Events

Date Code Title Description
ERR Error or correction

Free format text: THE INVENTOR HAS BEEN CORRECTED TO 3178343, COSSINS, AIMEE, C/O UNITS 4-10, THE QUADRANTBARTON LANEABINGDON OXFORDSHIRE OX14 3YS, GB; 3178344, BEARD, MATTHEW, C/O UNITS 4-10, THE QUADRANTBARTON LANEABINGDON OXFORDSHIRE OX14 3YS, GB; 3479705, PHILIP MARKS, IPSEN BIOPHARM LIMITED, ASH ROAD, WREXHAM INDUSTRIAL ESTATE, WREXHAM LL13 9UF, GB

Effective date: 20151124

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 OCT 2021 BY CPA GLOBAL

Effective date: 20200917

LAPS Patent lapsed